News & Blog

InVitria Joins NSF Engineering Research Center for Cell Manufacturing Technologies (CMaT)

InVitria Presents ASGCT 2026 Data on rHSA for Lentiviral Vector Manufacturing

InVitria Showcases Exbumin and Optibumin 25 at IPEC Excipient World: Biologics Summit

Beyond Synthetic Surfactants: The Case for Recombinant Human Serum Albumin (rHSA) as an Ideal Alternative to Poloxamer 188

InVitria and Cellevate Partner on Vaccine Manufacturing

Replacing the “Necessary Evil”: Recombinant Human Serum Albumin as a Chemically Stable Alternative to Polysorbates in Biopharmaceutical Formulation

The “Cheap” Albumin Paradox: The Actuarial Cost of Serum Albumin in Biomanufacturing

Supply Chain Resilience: The Fragility and Finite Nature of Serum-Derived Raw Materials

Safety and Contamination Risks: The Testing Burden and Persistent Threats

Variability and Failed Lots: The Hidden Quality Control Challenge of Serum & Serum-Derived Products

Consistency Is the New Compliance

In Memory of Dr. William J. Rutter (1927–2025)

Why Border Disruptions Threaten Blood-Derived Raw Materials—and What Biomanufacturers Can Do About It

InVitria Launches OptiLeukin 2 Recombinant Interleukin-2

Albumin in Drug Delivery: Cancer’s Unexpected Achilles’ Heel

Why Do Some Biologics Cross the Finish Line—While Others Crash and Burn?

InVitria Launches Optibumin 25 rHSA

Cryopreservation Just Got Better with Optibumin® 25

How Regulatory Bodies Are Driving the Shift to Animal-Origin-Free Solutions in Cell Therapy and Vaccine Development

Innovative Solutions in Closed-System Biomanufacturing: Exploring the Tools and Technologies Driving Sterility and Efficiency

Evolving Challenges in Closed-System Biomanufacturing

Optibumin vs Traditional Albumin: Comparing Performance in Cell Wash Applications

Scaling Innovation: How DiscGenics and InVitria are Leading the Future of Cell Therapy

Solving the Vaccine Supply Challenge

SARS-CoV2 and Influenza – Double Threat

High-Performance Production of Viral Vectors for Cell and Gene Therapy Using OptiPEAK HEK293t Complete Media

Recombinant Virus Platforms are Out in Front in the Race to Develop Vaccines Against SARS-CoV-2 and COVID-19 Disease

Controlling Impurities in Cell Culture Media

BioInnovation on Parade: Philly Stands Proud for BIO 2019!

Explore the Latest Developments in T-reg Research and Clinical Application

Exploring the Latest Research and Opportunities in T-reg Therapy

ASGCT 2019: Remarkable Milestones and Achievements in Cell and Gene Therapy

Recombinant Albumin for Stabilization of Live-Attenuated Viral Vaccines

Universal Vaccine Against Seasonal Influenza Steps Closer to Reality with the Results of FluGen Phase 2 Clinical Trial

ECI Conference 2019: The Latest Innovations and Trends in Cell & Gene Therapy

Phacilitate 2019 and World Stem Cell Summit

Join InVitria at ECI 2019

Join InVitria at Phacilitate 2019

Happy Holidays from the InVitria Team!

BIO Europe 2018: From Lab Innovations to Commercial Realities

InVitria Expands Operations to Anschutz Medical Campus in the Denver Metro Area

BIO 2018: The Emergence of Gene & Cell Therapy

InVitria at the American Association of Immunologists 2018 Conference

InVitria’s Top Insights from ISCT 2018 – Montreal

3 Takeaways from the World Vaccine Congress 2018